Valion Bio (Nasdaq:VBIO): Oral Mucosal Entolimod Could Offer a New Needle-Free Deployment Path to Support Growing Need for Scalable Civilian Radiation Preparedness Should Nuclear Infrastructure Expand to Support Data Centers
Rising electricity demand from AI and data centers is driving plans to expand nuclear power capacity, possibly including on-site small modular reactors (SMRs)¹Medical countermeasures need to scale along with that infrastructureValion is …
Rising electricity demand from AI and data centers is driving plans to expand nuclear power capacity, possibly including on-site small modular reactors (SMRs)¹
Medical countermeasures need to scale along with that infrastructure
Valion is developing an oral mucosal formulation of Entolimod that could potentially provide a needle-free administration option for acute radiation syndrome ("ARS")
SAN ANTONIO, TX / ACCESS Newswire / October 9, 2026 / As nuclear power assumes an increasingly important role in meeting the growing electricity requirements of artificial intelligence, data centers and other digital infrastructure, the expansion of the U.S. nuclear-energy landscape that has been increasingly making headlines across the country is also highlighting the importance of resilient emergency preparedness and medical countermeasures for potential radiological and nuclear events.
Against this backdrop, Valion Bio, Inc. (Nasdaq:VBIO) ("Valion" or the "Company"), a clinical-stage biopharmaceutical company developing biologics that activate innate immune pathways for cytoprotection, believes the evolving U.S. nuclear energy landscape reinforces the importance of advancing medical countermeasures that could be deployed rapidly and at population scale in the event of a radiological or nuclear emergency.
"The significance of the changing nuclear landscape1 extends beyond how electricity is generated - it also raises important questions about how communities and emergency systems prepare for low-probability, high-consequence radiation events," said Dean Zikria, Interim Chief Executive Officer of Valion Bio.
Entolimod, Valion's investigational drug biologic being developed for ARS is designed to potentially protect cells from severe damage or death both prophylactically (pre-exposure) and therapeutically (post-exposure). Historically administered by intramuscular injection, Entolimod is now the subject of an oral mucosal formulation-development program with Shear Kershman Laboratories ("SKL") utilizing SKL's proprietary BioViscid drug-delivery platform.
Valion and SKL recently successfully completed formulation work under their ongoing program to develop a novel oral mucosal formulation of Entolimod. The resulting BioViscid-Entolimod formulation is designed to enable absorption through the oral mucosa, potentially providing a needle-free alternative to injectable administration.

